Liquid Biopsy Market Size, Share, By Offering (Instruments, Reagents & Kits, and software and services), Biomarker (Circulating Tumor (CTC), Circulating Nucleic Acids, Exosomes, Circulating Biomarkers and Others), Technology (Next-generation Sequencing (N

Liquid Biopsy Market Size, Share, By Offering (Instruments, Reagents & Kits, and software and services), Biomarker (Circulating Tumor (CTC), Circulating Nucleic Acids, Exosomes, Circulating Biomarkers and Others), Technology (Next-generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), Indication (Lung Cancer, Breast Cancer, Prostate Cancer and Others), Sample Type (Blood, Urine, Saliva, and Others), Clinical Applications (Diagnosis & Screening, Treatment Selection, Drug Resistance, Prognosis, and Others), End-user (Hospitals & Laboratories, Specialty Clinics, Academic & Research Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

Liquid Biopsy Market accounted for US$ 1.32 billion in 2020 and is estimated to be US$ 7.92 billion by 2030 and is anticipated to register a CAGR of 19.8%. Liquid biopsy is a non-invasive alternative to surgical biopsies that allows doctors to acquire tumor-related information from a simple blood sample. The epidermal growth factor receptor (EGFR) gene alterations that arise in people with non-small cell lung cancer can be detected using a liquid biopsy test. Liquid biopsy detects tumour DNA in a blood sample, which can help doctors choose the best treatment for a specific patient. Lung, breast, and prostate cancer are the most common reasons for these biopsies.

The report “ Liquid Biopsy Market By Product Type (Reagents & Kits and Equipment), By Sample (Cell Free DNA, Circulating Tumor Cells, and Exosomes), By Application (Oncology Testing, Non-Invasive Prenatal Testing, and Transplant Care), By End User (Hospitals, Research Laboratories, Diagnostic Laboratories, and Patients) and By Region (North America, Asia Pacific, Europe, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030’’

Key Highlights:

• Guardant Health, Inc. (US) announced the Guardant360 Response test in June 2021, which identifies changes in the levels of circulating tumour DNA (ctDNA).
• F. Hoffmann-La Roche Ltd. (Switzerland) got extended claims for the cobas EGFR Mutation Test v2 from the US FDA in October 2020, allowing it to be used as a companion diagnostic (CDx) for a broader spectrum of medicines to treat non-small cell lung cancer (NSCLC).
• Biocept, Inc. (US) announced in March 2020 that it has reached an agreement with a second California-based independent physician association (IPA) to supply its Target Selector liquid biopsy test services to the network's physicians and patients.

Key Benefits of Purchasing This Report

Gain valuable insights into revenue projections for the overall market and its sub-segments, benefiting industry leaders and new entrants.

Enhance your understanding of the competitive landscape to refine business positioning and optimize go-to-market strategies.

Stay informed on the latest trends in the Liquid Biopsy Market, including key drivers, challenges, opportunities, and barriers.

Analyst View:

There has been a huge increase in the number of people diagnosed with cancer around the world. Environmental causes, cigarette consumption, infectious agents such as Hepatitis B and C, and lifestyle changes are all contributing to the increased cancer prevalence. Cancer is the second-leading cause of mortality worldwide, according to the World Health Organization. According to the International Agency for Research on Cancer (IARC), the cancer burden is expected to reach 19.3 million cases and 9.96 million cancer deaths by 2020. Reduced cost, early prognosis, therapy monitoring, detection of tumour heterogeneity, acquired drug resistance, and patient comfort are all advantages of liquid biopsy over traditional cancer diagnostics approaches (by eliminating the need for surgery). As a result, in the projection period, the preference for liquid biopsy will most certainly increase in tandem with the rise in cancer prevalence.

Segmentation:

By Offering:

• Instruments
• Reagents & Kits
• Software
• Services

By Biomarker:

• Circulating Tumor (CTC)
• Circulating Nucleic Acids
• Exosomes
• Circulating Biomarkers
• Others

By Technology:

• Next-generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)

By Indication:

• Lung cancer
• Breast cancer
• Prostate cancer
• Others

By Sample Type:

• Blood
• Urine
• Saliva
• Others

By Clinical Application:

• Diagnosis & Screening
• Treatment Selection
• Drug Resistance
• Prognosis
• Others

By End-user:

• Hospitals & Laboratories
• Specialty Clinics
• Academic& Research Centers
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• Malaysia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• GCC
• Israel
• South Africa
• Rest of Middle East & Africa

Competitive Landscape & their strategies of Liquid Biopsy Market:

• ANGLE plc
• Thermo Fisher Scientific, Inc.
• Guardant Health
• Personalis, Inc
• Bio-Rad Laboratories, Inc
• Illumina, Inc.
• Menarini Silicon Biosystems
• Myriad Genetics, Inc.
• Lucence Health Inc.
• Freenome Holdings, Inc
• Natera, Inc
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Epigenomics AG

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the market are included in the report.

Key Questions Answered in This Report

1. What was the size of the Liquid Biopsy Market in 2024?

2. What is the expected growth rate of the Liquid Biopsy Market during 2025-2035?

3. What are the key factors driving the Liquid Biopsy Market?

4. What is the breakup of the Liquid Biopsy Market based on the distribution channel?

5. What are the key regions in the Liquid Biopsy Market?

6. Who are the key players/companies in the Liquid Biopsy Market?

7. What are the drivers, restraints, and opportunities in the Liquid Biopsy Market?